Yes—a lawsuit filed by over 11,000 women alleges that L’Oreal deliberately downplayed safety concerns about hair relaxer products despite published scientific research indicating the products significantly increased cancer risk. The case stems from a landmark 2022 study by the National Institutes of Health following 33,000+ women, which found that frequent hair relaxer use was linked to a 2.4 times greater risk of developing uterine cancer compared to non-users. As of March 2026, L’Oreal faces a federal multidistrict litigation (MDL) involving 11,440 lawsuits, with the litigation currently in the discovery phase and no settlement announced yet.
The L’Oreal hair relaxer litigation raises critical questions about corporate accountability and consumer transparency. Companies including L’Oreal, SoftSheen Carson, and Revlon marketed these products as safe for regular use while scientific evidence accumulated linking them to uterine, endometrial, and ovarian cancers. This article explains what the scientific evidence shows, which products are involved, where the litigation currently stands, and what you need to know if you’ve used these products.
Table of Contents
- What Scientific Evidence Connects Hair Relaxers to Cancer Risk?
- What Products Are Named in the L’Oreal Hair Relaxer Litigation?
- How Did L’Oreal’s Safety Claims Fall Short of Scientific Findings?
- What Is the Current Status of the Hair Relaxer Class Action Litigation?
- What Chemicals in Hair Relaxers Raise Health Concerns?
- What Should Consumers Know About Hair Relaxer Health Risks?
- What Does the Future Hold for Hair Relaxer Litigation and Product Regulation?
What Scientific Evidence Connects Hair Relaxers to Cancer Risk?
The primary scientific foundation for the L’Oreal hair relaxer litigation comes from the NIH Sister Study, a long-term research project that began in 2003. This study followed over 33,000 women and collected detailed information about their personal care habits, including the frequency and duration of hair relaxer use. The study’s findings, published in 2022, revealed that women who used hair relaxers four or more times per year had a 2.4 times greater risk of developing uterine cancer compared to women who never used hair relaxers. This wasn’t a small-scale laboratory observation—it was data from thousands of women over decades, making it statistically strong and difficult to dismiss.
Hair relaxer products contain multiple chemicals that scientists classify as endocrine disruptors—substances that interfere with hormone regulation in the body. These include phthalates, heavy metals such as lead, and parabens. The scalp is highly vascular and absorbs substances readily, meaning these chemicals can enter the bloodstream through topical application. The risk increases with frequency of use because each application introduces these substances into the body, with cumulative exposure over years potentially leading to hormonal imbalances and cellular changes that can trigger cancer development.
What Products Are Named in the L’Oreal Hair Relaxer Litigation?
The litigation focuses on specific L’Oreal brands, primarily Dark and Lovely and Just for Me, both products marketed heavily to Black women and other women of color. Dark and Lovely, owned by L’Oreal subsidiary SoftSheen Carson, has been sold for decades as an affordable, accessible hair straightening solution. Just for Me, another L’Oreal product line, similarly positioned itself as a consumer-friendly relaxer brand. Beyond L’Oreal, other defendants include SoftSheen Carson independently and Revlon’s Realistic brand.
These products were among the most widely used chemical hair relaxers in the United States, particularly in communities where the products were actively marketed and recommended by stylists. However, not all hair relaxer formulations carried identical risk. The chemical composition of relaxers varies—some use sodium hydroxide as the primary active ingredient, while others use guanidine hydroxide or calcium hydroxide. The NIH Sister Study didn’t distinguish between specific formulation types, meaning the 2.4x risk figure applies broadly to regular hair relaxer use. This is a limitation in applying the research to individual product decisions, though regulators and plaintiffs argue that companies should have conducted their own safety studies on the specific formulations they sold rather than relying on general assumptions of safety.
How Did L’Oreal’s Safety Claims Fall Short of Scientific Findings?
L’Oreal and competing hair relaxer manufacturers marketed their products with messaging emphasizing safety for at-home and professional use. Warning labels existed on these products, but they typically focused on skin irritation and allergic reactions—not systemic health risks like cancer. The misrepresentation claim centers on the gap between what companies said (implicitly, through marketing and labeling) and what scientific research documented.
Companies did not prominently disclose that frequent users faced elevated cancer risk, nor did they fund independent studies to verify the safety of their specific formulations after concerns emerged. The litigation argues this constitutes negligent misrepresentation because companies had access to published research and failed to adequately warn consumers or modify their products. A specific example of this disconnect: a woman using Dark and Lovely relaxer every six weeks for 20 years (approximately 86 applications) would fall well into the “4+ times per year” category that the NIH study flagged as high-risk—yet the product labeling and marketing did not communicate this level of cancer risk. The company’s silence on a published scientific finding can constitute misrepresentation under consumer protection law, particularly in a category where women of color have been disproportionately marketed to.
What Is the Current Status of the Hair Relaxer Class Action Litigation?
As of March 2026, the L’Oreal hair relaxer litigation exists as a federal multidistrict litigation (MDL) with 11,440 lawsuits consolidated in federal court—not a single unified class action. A status hearing was held on March 5, 2026, to assess discovery progress. Fact discovery was scheduled to wrap by February 2026, with expert discovery timelines currently in development. The litigation remains in early-to-mid stages, meaning the core factual disputes and expert testimony on causation have not yet been fully litigated.
One critical comparison: this timeline mirrors other major product liability MDLs that took 5-10 years to resolve. Bellwether trials—the first test cases to go to trial, designed to gauge how juries respond to the evidence—are scheduled for 2027. Expert ruling decisions are not expected until no earlier than late 2026. Historically, settlements in large MDLs do not materialize until the litigation approaches trial date, when both sides have better clarity on jury reaction risk and financial exposure. Given that we are still 6-12 months away from bellwether trials, a settlement announcement is unlikely in 2026 and more probable in 2027-2028.
What Chemicals in Hair Relaxers Raise Health Concerns?
The chemical profile of hair relaxers includes several substances flagged by regulatory agencies as potential health hazards. Phthalates, which make relaxer formulas more pliable and easier to apply, are classified as endocrine disruptors that can mimic or block hormone activity. Heavy metals including lead and cadmium can accumulate in the body over repeated exposures and have been linked to reproductive health issues. Parabens, used as preservatives, have been studied for potential estrogenic effects—the ability to act like estrogen in the body.
When combined, these chemicals create a compounding risk scenario where regular use exposes the scalp and bloodstream to multiple hormone-disrupting substances simultaneously. A warning about causation claims: while the NIH Sister Study shows a strong association between frequent hair relaxer use and uterine cancer, establishing direct causation in individual cases remains scientifically complex. A woman who developed uterine cancer and used hair relaxers may have multiple contributing factors (age, family history, obesity, hormone use). courts and juries will need to evaluate whether hair relaxer use was a substantial factor in her cancer development, which is why expert testimony and causation analysis will dominate the expert discovery phase and upcoming bellwether trials. The litigation is not arguing that hair relaxers cause cancer in every user, but rather that the increased statistical risk should have been disclosed and that product reformulation should have been considered.
What Should Consumers Know About Hair Relaxer Health Risks?
If you have used hair relaxers regularly, particularly over many years, understanding your health risk level is important. The NIH Sister Study specifically flagged women using relaxers four or more times per year—roughly every three months—as the high-risk group. Women who used relaxers less frequently (one to three times per year) showed lower elevated risk, though still above non-users.
This frequency threshold matters because it suggests there may be a cumulative dose-response relationship: the more often you expose your scalp and body to these chemicals, the higher your lifetime cancer risk. For anyone concerned about past hair relaxer use, speaking with a dermatologist or oncologist can help contextualize individual risk. These specialists can discuss family history, other risk factors for uterine cancer (age, obesity, estrogen exposure, tamoxifen use), and appropriate screening or monitoring. Simply having used hair relaxers does not guarantee cancer development, but it does elevate statistical risk, which is medically important information for informed health decisions going forward.
What Does the Future Hold for Hair Relaxer Litigation and Product Regulation?
The bellwether trials in 2027 will be watched closely by regulators, consumer advocates, and the hair care industry. These trials will establish precedent for how courts evaluate causation in hair relaxer cases and what damages juries assign to affected plaintiffs. A plaintiff win in bellwether trials typically accelerates settlement discussions; a defendant win can prompt dismissals. Either outcome reshapes the litigation landscape for the remaining 11,000+ cases.
Looking ahead, the litigation may also prompt regulatory action. The FDA has limited authority over cosmetics but has been increasing scrutiny of chemical ingredients linked to health harms. A significant settlement or court judgment in the L’Oreal cases could motivate the agency to require chemical reformulation or enhanced warning labels for all hair relaxer products. Consumer awareness is already shifting, with some manufacturers developing “natural” or chemical-free alternatives marketed as safer options, reflecting the market response to growing health concerns.